Management of rapidly progressive glomerulonephritis.
Glassock
R
R
Department of Medicine, University of California, Los Angeles, UCLA School of Medicine, USA.
Henrich
W L
WL
D000465:Algorithms; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D003371:Cough / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003663:Decision Trees; D003937:Diagnosis, Differential; D018450:Disease Progression; D005334:Fever / Q000209:etiology; D005921:Glomerulonephritis / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D012008:Recurrence; D012017:Referral and Consultation; D014657:Vasculitis / Q000097:blood / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D015431:Weight Loss
D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008775:Methylprednisolone